Burden of Inflammatory Bowel Disease in Portugal

Dados básicos

Código:
Estudo Clínico Académico (Inflammatory Bowel)
Protocolo:
Estudo Clínico Académico (Inflammatory Bowel)
EUDRACT:
NCT:
Centro:
Dotação:
Ano de início:
2023
Ano de conclusão:
Estudos observacionais Nacional Não Financiado Outros

Objectivos do projeto

Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários

Documentos

  • Não há documentos

Participantes

Unidades de investigação

Stakeholders - Promotores

FMUP

Outputs do ensaio clínico


Accuracy of information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO guidelines

Farrugia, Y.; (...); Ellul, P.

Meeting Abstract. 10.1093/ecco-jcc/jjae040. 2024


An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

D'Amico, Ferdinando; (...); Allocca, Mariangela

Article. 10.1111/eci.14283. 2024

  • Open Access.

Angiotensin-converting enzymes 1 and 2 in the feces: presence and catalytic activity in the rat 2,4,6-trinitrobenzene sulfonic acid-induced model of colitis

Ferreira Duarte, M; (...); Morato, M

Article. 10.1111/jgh.16541. 2024

  • Open Access.

Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review

Gomes, SF; (...); Magro, F

Review. 10.3390/ijms252312852. 2024

  • Open Access.

Author's Reply: ``Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?''

Sousa, Paula, Magro, Fernando

Editorial Material. 10.1016/j.dld.2023.12.006. 2024


Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study

Gisbert, Javier P.; (...); Vermeire, Severine

Article. 10.1093/ibd/izae162. 2024

  • Open Access.

Benefit-risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study

Gisbert, J. P.; (...); Vermeire, S.

Meeting Abstract. 2024


Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST

Peyrin-Biroulet, Laurent; (...); Danese, Silvio

Article. 10.1111/apt.17751. 2024

  • Open Access.

Clinical Trials in Portugal: Past and Future. Position Paper from the Colleges of Clinical Pharmacology and Pharmaceutical Medicine

Borges-Carneiro, Filipa; (...); Magro, FERNANDO

Editorial Material. 10.20344/amp.21371. 2024

  • Open Access.

Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

Allocca, Mariangela; (...); Fiorino, Gionata

Article. 10.1002/ueg2.12492. 2024

  • Open Access.

Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective

Parigi, TL; (...); Peyrin-Biroulet, L

Review. 10.1002/ueg2.12671. 2024

  • Open Access.

Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper

Rosini, F.; (...); Svrcek, M.

Meeting Abstract. 2024


Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis

Rubin, David T.; (...); Peyrin-Biroulet, Laurent

Article. 10.1093/ibd/izae204. 2024


Early Disease Clearance With Etrasimod and Correlation With Week 52 Outcomes and Biomarkers: A Post Hoc Analysis of the Phase 3 ELEVATE UC Trials

Magro, FERNANDO; (...); Feagan, Brian G.

Meeting Abstract. 2023


EARLY HISTO-ENDOSCOPIC RESPONSE PREDICTS CLINICAL OUTCOMES WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS

Magro, F.; (...); Daperno, M.

Meeting Abstract. 2024


Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial

Magro, Fernando; (...); Reinisch, Walter

Article. 10.1016/j.cgh.2023.11.010. 2024

  • Open Access.

Efficacy and safety of probiotics in inflammatory bowel disease: an umbrella review and updated meta-analysis of randomized controlled trials

Estevinho, M. M.; (...); Magro, F.

Meeting Abstract. 2024


Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extension

D'Haens, G.; (...); Blumenstein, I.

Meeting Abstract. 2024


Efficacy of Upadacitinib in Patients With One or More Prior Surgical Procedures for Crohn's Disease: A Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials

Loftus, E; (...); Lichtenstein, G

Meeting Abstract. 10.14309/01.ajg.0000995764.89379.2a. 2023

  • Open Access.

Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease

De Sousa, H. Tavares; (...); Magro, F.

Meeting Abstract. 2024


Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials

Pai, Rish K.; (...); Magro, FERNANDO

Review. 10.1080/17474124.2024.2326838. 2024

  • Open Access.

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

Solitano, Virginia; (...); Danese, Silvio

Review. 10.1016/j.autrev.2023.103504. 2024

  • Open Access.

Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 a) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis

Poenariu, Ioan Sabin; (...); Estevinho, Maria Manuela

Article. 10.3390/biomedicines11123137. 2023

  • Open Access.

Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results

D'Amico, F.; (...); Dignass, A.

Meeting Abstract. 2024


Managing Ulcerative Colitis and Crohn's Disease: Should the Target Be Endoscopy, Histology, or Both?

Magro, Fernando, Estevinho, Maria Manuela, Valois, Andre

Article. 10.1093/jcag/gwad034. 2023

  • Open Access.

Microbiota therapeutics for inflammatory bowel disease: the way forward

Bethlehem, Lukas; (...); Colombel, Jean-Frederic

Article. 10.1016/S2468-1253(23)00441-7. 2024

  • Open Access.

Mucosal transcriptomic profiles associated with clinical response in patients with Ulcerative Colitis receiving filgotinib

Magro, F.; (...); Reinisch, W.

Meeting Abstract. 2024


Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?

Temido, Maria Jose; (...); Peyrin-Biroulet, Laurent

Editorial Material. 10.1093/ecco-jcc/jjae136. 2024

  • Open Access.

Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis

Estevinho, Maria Manuela; (...); Magro, Fernando

Review. 10.1111/apt.18315. 2024


Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years

Imbrizi, M, Magro, F, Coy, CSR

Review. 10.3390/ph16091272. 2023

  • Open Access.

Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus

D'Amico, F; (...); Danese, S

Article. 10.3390/jcm12196350. 2023

  • Open Access.

Practical management of mild-to-moderate ulcerative colitis: an international expert consensus

D'Amico, Ferdinando; (...); Danese, Silvio

Review. 10.1080/17474124.2024.2397650. 2024

  • Open Access.

Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus

Fantini, Massimo Claudio; (...); Ghosh, Subrata

Article. 10.1093/ecco-jcc/jjae026. 2024

  • Open Access.

Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD international consensus

Fantini, M. C.; (...); Ghosh, S.

Meeting Abstract. 2024


Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus

Olivera, Pablo A.; (...); Peyrin-Biroulet, Laurent

Article. 10.1016/j.dld.2024.03.010. 2024

  • Open Access.

Proactive Infliximab monitoring improves the rates of transmural remission in Crohn's disease - a propensity score matched analysis

Fernandes, S. R.; (...); Magro, F.

Meeting Abstract. 2024


Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis

Fernandes, SR; (...); Magro, F

Article. 10.1093/ibd/izad272. 2023


Proportion of IBD patients with suboptimal control in daily clinical practice - real-world evidence from the IBD Podcast study

Dignass, A.; (...); Leitner, C.

Meeting Abstract. 2024


Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study

D'Amico, Ferdinando; (...); Dignass, Axel

Article. 10.1002/ueg2.12572. 2024

  • Open Access.

Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trial

Vermeire, S.; (...); Bolca, S.

Meeting Abstract. 2024


The degree of bowel remission predicts phenotype progression in Crohn's disease

Fernandes, Samuel Raimundo; (...); Magro, FERNANDO

Article. 10.1002/ueg2.12581. 2024

  • Open Access.

The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients

Magro, F.; (...); Santiago, M.

Meeting Abstract. 2024


The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients

Magro, Fernando; (...); Santiago, Mafalda

Article. 10.1093/ecco-jcc/jjae014. 2024


Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab

Sousa, P; (...); Magro, F

Article. 10.1016/j.dld.2023.10.027. 2024

  • Open Access.

Tight control using fecal calprotectin and early disease intervention increase the rates of transmural remission in Crohn's disease

Fernandes, SR; (...); Magro, F

Article. 10.1002/ueg2.12497. 2023

  • Open Access.

Transmural Remission Associates with a Lower Risk of Phenotype Progression in Crohn's Disease

Fernandes, S. R.; (...); Magro, F.

Meeting Abstract. 2024


Use of intestinal ultrasound influences the proportion of suboptimally controlled patients: IBD Podcast Study results

Dignass, A.; (...); Magro, F.

Meeting Abstract. 2024


Partilhar